Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALUMIS INC.ALMS · Entity 4816 | Director | September 04, 2026 | September 10, 2026 |
| Jiya Acquisition Corp.JYAC · Entity 123583 | Director · 10% owner | September 23, 2022 | September 23, 2022 |
| Kalaris Therapeutics, Inc.KLRS · Entity 6805 | Director | June 03, 2026 | June 04, 2026 |
| LENZ Therapeutics, Inc.GRPH · Entity 6475 | 10% owner | April 11, 2022 | April 13, 2022 |
| Mineralys Therapeutics, Inc.MLYS · Entity 4432 | Director · 10% owner | February 19, 2026 | February 21, 2026 |
| Neurogene Inc.NGNE · Entity 5160 | 10% owner | November 26, 2024 | November 27, 2024 |
| Principia Biopharma Inc.PRNB · Entity 146423 | Director | September 13, 2018 | January 11, 2019 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | Director | June 04, 2026 | June 08, 2026 |
| Seagen Inc.SGEN · Entity 13956 | Director | May 15, 2020 | May 19, 2020 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | September 16, 2024 | September 18, 2024 |
| aTYR PHARMA INCLIFE · Entity 7233 | Director | May 09, 2017 | May 11, 2017 |
| vTv Therapeutics Inc.VTVT · Entity 6614 | Director | June 26, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALUMIS INC.
Report date September 04, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 4,937,026 |
Last balance in matching sequence
After 2026-09-08 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-09-04 · Purchase · Acquired 220,070 · Balance 4,711,801 F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.02 to $11.60, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Row 3 · 2026-09-08 · Sale · Disposed 48,066 · Balance 4,663,735 F4: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs. F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $10.38 to $10.91, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Row 5 · 2026-09-08 · Purchase · Acquired 273,291 · Balance 4,937,026 F4: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs. F6: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.26 to $10.835, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Samsara Opportunity Fund, L.P. | 2,298,783 |
Last balance in matching sequence
After 2026-09-08 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2026-09-04 · Purchase · Acquired 220,070 · Balance 2,073,558 F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.02 to $11.60, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F3: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Row 4 · 2026-09-08 · Sale · Disposed 48,065 · Balance 2,025,493 F4: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs. F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $10.38 to $10.91, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Row 6 · 2026-09-08 · Purchase · Acquired 273,290 · Balance 2,298,783 F4: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs. F6: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.26 to $10.835, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F3: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 3,553 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 3,553 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.02 to $11.60, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F2: Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F3: Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
F4: The sales and purchases on September 8, 2026 were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 48,066 shares in the case of Samsara LP and 48,065 shares in the case of Samsara Opportunity Fund, resulting in short-swing profit liability under Section 16(b). The Reporting Person has agreed to disgorge to the Issuer the short-swing profit realized in connection with these transactions, less transaction costs.
F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $10.38 to $10.91, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.26 to $10.835, inclusive. The Reporting Person undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Jiya Acquisition Corp.
Report date September 23, 2022 · Filed September 23, 2022
Jointly reported with Jiya Holding Co LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 2,437,114 |
Reported balance
After 2022-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-23 · Other · Acquired 29,667 · Balance 2,437,114 F1: The shares of Class B Common Stock of the Issuer ("Class B Shares") will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date. F2: Reflects the forfeiture of Class B Shares held by an employee of the Issuer upon such employee's resignation from the Issuer. As a result, these Class B Shares were automatically returned to Jiya Holding Company LLC ("Jiya Holdco") for no consideration ($0). F3: Reflects the Class B Shares held by Jiya Holdco. This amount does not reflect the 30,000 Class B shares directly held by Dr. Srinivas Akkaraju M.D., Ph.D. F4: Jiya HoldCo is wholly owned by Samsara BioCapital, L.P. ("Samsara LP"). Dr. Akkaraju has voting and dispositive control over the reported securities held by Jiya Holdco via Dr. Akkaraju's control of Samsara LP's general partner, Samsara BioCapital GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B Common Stock of the Issuer ("Class B Shares") will automatically convert into shares of Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis (subject to certain adjustments for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) concurrently with or immediately following the consummation of the Issuer's initial business combination, as described in the section entitled "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-249808) filed with the Securities and Exchange Commission on November 16, 2020. The Class B Shares have no expiration date.
F2: Reflects the forfeiture of Class B Shares held by an employee of the Issuer upon such employee's resignation from the Issuer. As a result, these Class B Shares were automatically returned to Jiya Holding Company LLC ("Jiya Holdco") for no consideration ($0).
F3: Reflects the Class B Shares held by Jiya Holdco. This amount does not reflect the 30,000 Class B shares directly held by Dr. Srinivas Akkaraju M.D., Ph.D.
F4: Jiya HoldCo is wholly owned by Samsara BioCapital, L.P. ("Samsara LP"). Dr. Akkaraju has voting and dispositive control over the reported securities held by Jiya Holdco via Dr. Akkaraju's control of Samsara LP's general partner, Samsara BioCapital GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein.
Kalaris Therapeutics, Inc.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2036-06-02 | Direct | 9,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 9,000 · Balance 9,000 F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
LENZ Therapeutics, Inc.
Report date April 11, 2022 · Filed April 13, 2022
Jointly reported with Samsara BioCapital, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 8,459,314 |
Last balance in matching sequence
After 2022-04-12 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-04-11 · Purchase · Acquired 74,464 · Balance 8,109,314 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.97 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. Row 2 · 2022-04-12 · Purchase · Acquired 350,000 · Balance 8,459,314 F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.05 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy 436, L.P. | 37,753 |
Reported balance
Holding disclosure · report date 2022-04-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 37,753 F4: Shares are held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.97 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.05 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4: Shares are held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein.
Mineralys Therapeutics, Inc.
Report date February 19, 2026 · Filed February 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,200 |
Reported balance
After 2026-02-19 transaction · row 1
1 source rowRow 1 · 2026-02-19 · Grant · Acquired 6,200 · Balance 6,200 F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.06 · Expires 2036-02-19 | Direct | 8,300 |
Reported balance
After 2026-02-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-19 · Grant · Acquired 8,300 · Balance 8,300 F3: The stock option vests in 12 substantially equal monthly installments following the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,871,018 |
Reported balance
Holding disclosure · report date 2026-02-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,871,018 F2: Of this amount, 588,235 shares are directly held by Samsara Opportunity Fund, L.P. (Samsara Opp LP). Samsara Opportunity Fund GP, LLC (Samsara Opp GP) is the general partner of Samsara Opp LP and may be deemed to beneficially own the securities held by Samsara Opp LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara Opp LP and, accordingly, may be deemed to beneficially own the shares held by Samsara Opp LP. Also, of this amount, 5,282,783 shares are directly held by Samsara BioCapital L.P. (Samsara LP). Samsara BioCapital GP, LLC (Samsara LLC) is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.
F2: Of this amount, 588,235 shares are directly held by Samsara Opportunity Fund, L.P. (Samsara Opp LP). Samsara Opportunity Fund GP, LLC (Samsara Opp GP) is the general partner of Samsara Opp LP and may be deemed to beneficially own the securities held by Samsara Opp LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara Opp LP and, accordingly, may be deemed to beneficially own the shares held by Samsara Opp LP. Also, of this amount, 5,282,783 shares are directly held by Samsara BioCapital L.P. (Samsara LP). Samsara BioCapital GP, LLC (Samsara LLC) is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
F3: The stock option vests in 12 substantially equal monthly installments following the date of grant.
Neurogene Inc.
Report date November 26, 2024 · Filed November 27, 2024
Jointly reported with Samsara BioCapital GP, LLC, Samsara BioCapital, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 1,717,127 |
Last balance in matching sequence
After 2024-11-26 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2024-11-26 · Purchase · Acquired 20,748 · Balance 1,689,105 F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Row 2 · 2024-11-26 · Purchase · Acquired 10,803 · Balance 1,699,908 F3: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Row 3 · 2024-11-26 · Purchase · Acquired 15,219 · Balance 1,715,127 F4: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Row 4 · 2024-11-26 · Purchase · Acquired 2,000 · Balance 1,717,127 F5: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F2: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Principia Biopharma Inc.
Report date September 13, 2018 · Filed January 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2028-09-12 | Direct | 20,475 |
Reported balance
After 2018-09-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-13 · Grant · Acquired 20,475 · Balance 20,475 F1: The stock option vests in equal monthly installments over a three year period, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in equal monthly installments over a three year period, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
Scholar Rock Holding Corp
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,971 |
Reported balance
After 2026-06-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 6,839 · Balance 27,971 F1: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2027 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2: Consists of 21,132 shares of common stock and 6,839 RSUs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.33 · Expires 2036-06-04 | Direct | 4,310 |
Reported balance
After 2026-06-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-04 · Grant · Acquired 4,310 · Balance 4,310 F5: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting, subject to continued service to the Issuer through such date. |
| Common StockSEC Table I · non-derivative | IndirectBy Samsara Opportunity Fund, L.P. | 530,038 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 530,038 F3: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 6,367,614 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,367,614 F4: Securities are directly held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2027 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date.
F2: Consists of 21,132 shares of common stock and 6,839 RSUs.
F3: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
F4: Securities are directly held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
F5: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting, subject to continued service to the Issuer through such date.
Seagen Inc.
Report date May 15, 2020 · Filed May 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,503 |
Reported balance
After 2020-05-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-15 · Grant · Acquired 1,335 · Balance 41,503 F1: These restricted stock units will be settled in common stock upon vesting. F2: These restricted stock units shall vest in full on May 15, 2021. F3: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $160.33 · Expires 2030-05-15 | Direct | 3,171 |
Reported balance
After 2020-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-15 · Grant · Acquired 3,171 · Balance 3,171 |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units will be settled in common stock upon vesting.
F2: These restricted stock units shall vest in full on May 15, 2021.
F3: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
Syros Pharmaceuticals, Inc.
Report date September 16, 2024 · Filed September 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,333 |
Reported balance
After 2024-09-16 transaction · row 1
1 source rowRow 1 · 2024-09-16 · Exercise / conversion · Acquired 2,667 · Balance 9,333 F1: Represents shares of common stock received upon vesting of a restricted stock unit ("RSU") award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,667 |
Reported balance
After 2024-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-09-16 · Exercise / conversion · Disposed 2,667 · Balance 2,667 F2: Each RSU represents the contingent right to receive one share of the issuer's common stock. F3: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock received upon vesting of a restricted stock unit ("RSU") award.
F2: Each RSU represents the contingent right to receive one share of the issuer's common stock.
F3: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.
aTYR PHARMA INC
Report date May 09, 2017 · Filed May 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2027-05-09 | Direct | 20,000 |
Reported balance
After 2017-05-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-09 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 09, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 09, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors.
vTv Therapeutics Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.08 · Expires 2036-06-26 | Direct | 16,983 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 6,000 · Balance 16,983 F1: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aravive, Inc.
Report date April 08, 2020 · Filed April 09, 2020
Section 16 reporting ended · disclosed 2020-04-09. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
CARGO Therapeutics, Inc.
Report date May 30, 2024 · Filed June 04, 2024
Jointly reported with Samsara BioCapital GP, LLC, Samsara BioCapital, L.P.
Section 16 reporting ended · disclosed 2024-06-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 4,415,689 |
Reported balance
After 2024-05-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-05-30 · Purchase · Acquired 294,000 · Balance 4,415,689 F1: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
CHINOOK THERAPEUTICS, INC.
Report date August 11, 2023 · Filed August 11, 2023
Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 3,300 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. |
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 5,161,888 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. F2: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.77 · Expires 2030-10-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-11 · Disposition to issuer · Disposed 23,522 · Balance 0 F3: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.81 · Expires 2031-06-03 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-11 · Disposition to issuer · Disposed 5,948 · Balance 0 F4: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-11 · Disposition to issuer · Disposed 13,300 · Balance 0 F4: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
F2: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein.
F3: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F4: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-11-08 · Other · Disposed 37,887 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 8,111 · Balance 0 F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-11-08 · Other · Disposed 640,688 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 12,089 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $210.36 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-11-08 · Disposition to issuer · Disposed 275 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $183.62 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-11-08 · Disposition to issuer · Disposed 1,750 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $145.22 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-11-08 · Disposition to issuer · Disposed 1,598 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $122.01 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-11-08 · Disposition to issuer · Disposed 2,036 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $85.12 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-11-08 · Disposition to issuer · Disposed 2,748 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.25 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-11-08 · Disposition to issuer · Disposed 2,174 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-11-08 · Disposition to issuer · Disposed 2,966 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein.
F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2020 Filed May 7, 2020 19:58 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 8,500 | $167.26 | $1,421,710.00 |
DisclosureSEC source: 0001203311-20-000025 · edgardoc.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,168 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $167.02 to $167.70. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 05, 2020 Filed May 7, 2020 19:58 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 8,500 | $20.06 | $170,510.00 |
DisclosureSEC source: 0001203311-20-000025 · edgardoc.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2019 Filed Dec 2, 2019 21:05 UTC | Aravive, Inc. ARAV · Entity 114535 | PurchaseCommon Stock | 133,333 | $7.50 | $999,997.50 |
DisclosureSEC source: 0000899243-19-028342 · doc4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 576,066 F1 · ownership.nature: The shares of common stock were purchased in a public underwritten offering completed by Aravive, Inc. on December 2, 2019. The shares are held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 18:35 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,942 | $0.00 Strike: $19.02 | $0.00 |
DisclosureSEC source: 0001203311-19-000063 · edgardoc.xml · derivative · entry 6 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,942 shares Expires 2021-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options were fully vested on 5/20/12. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 18:35 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,558 | $0.00 Strike: $19.02 | $0.00 |
DisclosureSEC source: 0001203311-19-000063 · edgardoc.xml · derivative · entry 5 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,942 Underlying: Common Stock · 12,558 shares Expires 2021-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options were fully vested on 5/20/12. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 18:35 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 4,942 | $120.46 | $595,313.32 |
DisclosureSEC source: 0001203311-19-000063 · edgardoc.xml · nonDerivative · entry 4 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,168 F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $120.35 to $120.68. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 18:35 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 4,942 | $19.02 | $93,996.84 |
DisclosureSEC source: 0001203311-19-000063 · edgardoc.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 18:35 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 12,558 | $119.51 | $1,500,806.58 |
DisclosureSEC source: 0001203311-19-000063 · edgardoc.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,168 F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $119.00 to $119.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 18:35 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 12,558 | $19.02 | $238,853.16 |
DisclosureSEC source: 0001203311-19-000063 · edgardoc.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 20:24 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 7,500 | $0.00 Strike: $5.77 | $0.00 |
DisclosureSEC source: 0000899243-19-023558 · doc4.xml · derivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-09-11 F1 · shares: These options vest pro rata on a monthly basis commencing on October 12, 2019 for the next 12 months with full vesting, if not fully vested at such time, on the date of the Aravive Inc.'s next annual meeting of stockholders. Read SEC document |
| August 28, 2019 Filed Aug 30, 2019 14:32 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | PurchaseCommon Stock | 5,207 | $60.32 | $314,086.24 |
DisclosureSEC source: 0001104659-19-048230 · a4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 403,688 F1 · price: These purchases were executed in multiple trades at prices ranging from $60.01 to $60.32. The price reported above reflects the weighted average purchase price. Mr. Akkaraju hereby undertakes to provide full information regarding the number of shares and prices at which these purchases were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein. Read SEC document |
| August 22, 2019 Filed Aug 22, 2019 19:53 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,180 | $64.30 | $75,874.00 |
DisclosureSEC source: 0001104659-19-047003 · a4.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 398,481 F4 · price: These purchases were executed in multiple trades at prices ranging from $64.295 to $64.30. The price reported above reflects the weighted average purchase price. Mr. Akkaraju hereby undertakes to provide full information regarding the number of shares and prices at which these purchases were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:14 UTC Amendment | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | PurchaseCommon Stock | 1,180 | $64.30 | $75,874.00 |
DisclosureSEC source: 0001104659-19-047186 · a4a.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 398,481 F4 · price: These purchases were executed in multiple trades at prices ranging from $64.295 to $64.30. The price reported above reflects the weighted average purchase price. Mr. Akkaraju hereby undertakes to provide full information regarding the number of shares and prices at which these purchases were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein. Read SEC document |
| August 21, 2019 Filed Aug 22, 2019 19:53 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 29,000 | $67.12 | $1,946,480.00 |
DisclosureSEC source: 0001104659-19-047003 · a4.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 397,301 F3 · price: These purchases were executed in multiple trades at prices ranging from $66.73 to $67.53. The price reported above reflects the weighted average purchase price. Mr. Akkaraju hereby undertakes to provide full information regarding the number of shares and prices at which these purchases were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 20:14 UTC Amendment | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | PurchaseCommon Stock | 29,000 | $67.12 | $1,946,480.00 |
DisclosureSEC source: 0001104659-19-047186 · a4a.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 397,301 F3 · price: These purchases were executed in multiple trades at prices ranging from $66.73 to $67.53. The price reported above reflects the weighted average purchase price. Mr. Akkaraju hereby undertakes to provide full information regarding the number of shares and prices at which these purchases were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 19:53 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 37,604 | $65.85 | $2,476,223.40 |
DisclosureSEC source: 0001104659-19-047003 · a4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 368,301 F1 · price: These purchases were executed in multiple trades at prices ranging from $65.80 to $66.15. The price reported above reflects the weighted average purchase price. Mr. Akkaraju hereby undertakes to provide full information regarding the number of shares and prices at which these purchases were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein. Read SEC document |
| August 20, 2019 Filed Aug 23, 2019 20:14 UTC Amendment | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | PurchaseCommon Stock | 37,604 | $65.85 | $2,476,223.40 |
DisclosureSEC source: 0001104659-19-047186 · a4a.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 368,301 F1 · price: These purchases were executed in multiple trades at prices ranging from $65.80 to $66.15. The price reported above reflects the weighted average purchase price. Mr. Akkaraju hereby undertakes to provide full information regarding the number of shares and prices at which these purchases were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,174 | $0.00 Strike: $82.25 | $0.00 |
DisclosureSEC source: 0001144204-19-031953 · tv524017_4.xml · derivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174 Underlying: Common Stock · 2,174 shares Expires 2029-06-20 F3 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-031953 · tv524017_4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,526 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 20:14 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-19-036355 · doc4.xml · derivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| May 20, 2019 Filed May 22, 2019 21:34 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,038 | $0.00 Strike: $64.38 | $0.00 |
DisclosureSEC source: 0000899243-19-014429 · doc4.xml · derivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,038 Underlying: Common Stock · 7,038 shares Expires 2029-05-20 F3 · derivative.exercise_date: These options shall vest in full on May 20, 2020. Read SEC document |
| May 20, 2019 Filed May 22, 2019 21:34 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 2,963 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-014429 · doc4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,168 F1 · security: These restricted stock units will be settled in common stock upon vesting. F2 · date: These restricted stock units shall vest in full on May 20, 2020. Read SEC document |
| May 14, 2019 Filed May 14, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 119,760 | $83.50 | $9,999,960.00 |
DisclosureSEC source: 0001144204-19-026106 · tv521400_4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 330,697 F1 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,001 | $0.00 Strike: $31.90 | $0.00 |
DisclosureSEC source: 0001144204-19-022020 · tv519767_4.xml · derivative · entry 5 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 979 Underlying: Common Stock · 1,001 shares Expires 2023-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents a "cash exercise" of stock options pursuant to which the reporting person paid to the Issuer the exercise price of such options in cash. No shares were sold by the reporting person in connection with this transaction. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 2,499 | $0.00 Strike: $21.50 | $0.00 |
DisclosureSEC source: 0001144204-19-022020 · tv519767_4.xml · derivative · entry 4 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,499 shares Expires 2022-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents a "cash exercise" of stock options pursuant to which the reporting person paid to the Issuer the exercise price of such options in cash. No shares were sold by the reporting person in connection with this transaction. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 1,001 | $31.90 | $31,931.90 |
DisclosureSEC source: 0001144204-19-022020 · tv519767_4.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents a "cash exercise" of stock options pursuant to which the reporting person paid to the Issuer the exercise price of such options in cash. No shares were sold by the reporting person in connection with this transaction. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 2,499 | $21.50 | $53,728.50 |
DisclosureSEC source: 0001144204-19-022020 · tv519767_4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents a "cash exercise" of stock options pursuant to which the reporting person paid to the Issuer the exercise price of such options in cash. No shares were sold by the reporting person in connection with this transaction. Read SEC document |
| April 09, 2019 Filed Apr 11, 2019 20:37 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | PurchaseCommon Stock Warrants (rights to buy) · Derivative | 133,333 | Not disclosed Strike: $8.63 | Not disclosed |
DisclosureSEC source: 0001104659-19-020868 · a4.xml · derivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 133,333 Underlying: Common Stock · 133,333 shares Expires 2022-10-10 F1 · price: The reported securities were purchased for $7.50 per share of common stock and accompanying warrants. The shares of common stock and warrants were purchased in combination, with 0.25 warrants to purchase a share of common stock accompanying each share of common stock. F2 · ownership.nature: Securities held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these securities except to the extent of the Reporting Person's pecuniary interest therein. Read SEC document |
| April 09, 2019 Filed Apr 11, 2019 20:37 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | PurchaseCommon Stock | 533,332 | $7.50 | $3,999,990.00 |
DisclosureSEC source: 0001104659-19-020868 · a4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,593,270 F1 · price: The reported securities were purchased for $7.50 per share of common stock and accompanying warrants. The shares of common stock and warrants were purchased in combination, with 0.25 warrants to purchase a share of common stock accompanying each share of common stock. F2 · ownership.nature: Securities held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these securities except to the extent of the Reporting Person's pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 20:33 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 23,438 | $128.78 | $3,018,345.64 |
DisclosureSEC source: 0001104659-19-009925 · a4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 210,937 F1 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2018. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 02:27 UTC Amendment | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 4,688 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001213900-19-000331 · ownership.xml · derivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,688 Underlying: Common Stock · 4,688 shares Expires 2029-01-02 F1 · derivative.exercise_price: The reporting person is amending the Form 4 originally filed to report the correct exercise price, which is $3.61. The exercise price was incorrectly reported in the initial Form 4 due to a typographical error. F2 · shares: These options vest as follows: (i) 1,563 shares of common stock vest immediately upon grant and (ii) 625 will vest on a monthly basis over the next five months commencing on February 3, 2019 with full vesting, if not fully vested at such time, on the date of the Aravive Inc.'s next annual meeting of stockholders. F2 · derivative.exercise_date: These options vest as follows: (i) 1,563 shares of common stock vest immediately upon grant and (ii) 625 will vest on a monthly basis over the next five months commencing on February 3, 2019 with full vesting, if not fully vested at such time, on the date of the Aravive Inc.'s next annual meeting of stockholders. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 19:08 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 4,688 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0001213900-19-000275 · ownership.xml · derivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,688 Underlying: Common Stock · 4,688 shares Expires 2029-01-02 F1 · shares: These options vest as follows: (i) 1,563 shares of common stock vest immediately upon grant and (ii) 625 will vest on a monthly basis over the next five months commencing on February 3, 2019 with full vesting, if not fully vested at such time, on the date of the Aravive Inc.'s next annual meeting of stockholders. F1 · derivative.exercise_date: These options vest as follows: (i) 1,563 shares of common stock vest immediately upon grant and (ii) 625 will vest on a monthly basis over the next five months commencing on February 3, 2019 with full vesting, if not fully vested at such time, on the date of the Aravive Inc.'s next annual meeting of stockholders. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 17:55 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001203311-18-000091 · edgardoc.xml · derivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares vested in full on 5/14/10. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 17:55 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 5,000 | $8.38 | $41,900.00 |
DisclosureSEC source: 0001203311-18-000091 · edgardoc.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 22:33 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantCommon Stock | 27,456 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055192 · doc4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,815 F1 · price: Shares of common stock of the corporation known as Aravive Biologics, Inc. ("Aravive") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018, by and among the Issuer, Velo Merger Sub, Inc. and Aravive (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Aravive common stock was exchanged for 2.2801 shares of the Issuer's common stock, subject to adjustment for any reverse stock split. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every six shares of Issuer common stock outstanding and the Issuer changed its name to Aravive, Inc. All share and option numbers reflect the reverse stock split. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:14 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | ConversionSeries C Preferred Stock · Derivative | 208,480 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-057814 · a4.xml · derivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 208,480 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F1 · price: Each share of Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F2 · ownership.nature: Shares are held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:14 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | PurchaseCommon Stock | 175,000 | $17.00 | $2,975,000.00 |
DisclosureSEC source: 0001104659-18-057814 · a4.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 383,480 F2 · ownership.nature: Shares are held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:14 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | ConversionCommon Stock | 208,480 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-057814 · a4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 208,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F2 · ownership.nature: Shares are held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein. Read SEC document |
| September 13, 2018 Filed Jan 11, 2019 02:40 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | GrantDirector Stock Option (right to buy) · Derivative | 20,475 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-19-003362 · doc4.xml · derivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,475 Underlying: Common Stock · 20,475 shares Expires 2028-09-12 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over a three year period, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,748 | $0.00 Strike: $85.12 | $0.00 |
DisclosureSEC source: 0001144204-18-035422 · tv496989_4.xml · derivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,748 Underlying: Common Stock · 2,748 shares Expires 2028-06-20 F3 · derivative.exercise_date: All of the shares subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-035422 · tv496989_4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,456 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 20:24 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.95 | $0.00 |
DisclosureSEC source: 0001179110-18-008617 · edgar.xml · derivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| June 13, 2018 Filed Jun 16, 2018 01:44 UTC | Aravive, Inc. VSAR · Entity 114535 | PurchaseCommon Stock | 53,018 | $2.13 | $112,928.34 |
DisclosureSEC source: 0001104659-18-040532 · a4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,682,554 F1 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 22:34 UTC | Aravive, Inc. VSAR · Entity 114535 | PurchaseCommon Stock | 231,580 | $2.00 | $463,160.00 |
DisclosureSEC source: 0001104659-18-039258 · a4.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,629,536 F4 · price: Represents the weighted average purchase price of the Shares purchased ranging from a low of $1.93 to a high of $2.13 per share. The reporting person undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 22:34 UTC | Aravive, Inc. VSAR · Entity 114535 | PurchaseCommon Stock | 163,224 | $1.85 | $301,964.40 |
DisclosureSEC source: 0001104659-18-039258 · a4.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,397,956 F3 · price: Represents the weighted average purchase price of the Shares purchased ranging from a low of $1.80 to a high of $1.90 per share. The reporting person undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 22:34 UTC | Aravive, Inc. VSAR · Entity 114535 | PurchaseCommon Stock | 660,681 | $1.74 | $1,149,584.94 |
DisclosureSEC source: 0001104659-18-039258 · a4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,234,732 F1 · price: Represents the weighted average purchase price of the Shares purchased ranging from a low of $1.65 to a high of $1.80 per share. The reporting person undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein. Read SEC document |
| May 18, 2018 Filed May 22, 2018 20:16 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,260 | $0.00 Strike: $56.77 | $0.00 |
DisclosureSEC source: 0001203311-18-000041 · edgardoc.xml · derivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,260 Underlying: Common Stock · 9,260 shares Expires 2028-05-18 F3 · derivative.exercise_date: The option shall vest in full on May 18, 2019. Read SEC document |
| May 18, 2018 Filed May 22, 2018 20:16 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 3,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-18-000041 · edgardoc.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,205 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · deemedExecutionDate: Restricted stock units shall vest in full on May 18, 2019. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 17:10 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 234,375 | $64.00 | $15,000,000.00 |
DisclosureSEC source: 0001104659-18-023079 · a4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 234,375 F1 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:53 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | PurchaseCommon Stock | 209,424 | $9.55 | $1,999,999.20 |
DisclosureSEC source: 0001209191-18-006777 · doc4.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote 1 Disclosed balance after: 1,059,938 F1 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.